Our results of PAI1 contributing to the survival of fibroblast-protected cancer cells in the context of HER2 therapy resistance agree with previous reports in esophageal and pancreatic carcinomas that demonstrated PAI1-targeted therapy restored cancer cell sensitivity to chemotherapy [52, 53]. This evidence concerns the gene ERBB2 and exocrine pancreatic carcinoma.